Literature DB >> 17287181

Is there the potential for an epidemic of variant Creutzfeldt-Jakob disease via blood transfusion in the UK?

Paul Clarke1, Robert G Will, Azra C Ghani.   

Abstract

The discovery of three individuals suspected to have contracted variant Creutzfeldt-Jakob disease (vCJD) through blood transfusions has heightened concerns that a secondary epidemic via human-to-human transmission could occur in the UK. The Department of Health responded immediately to this threat by banning those who had received blood transfusions since 1980 from donating blood. In this paper, we conduct a sensitivity analysis to explore the potential size of a blood-borne vCJD epidemic and investigate the effectiveness of public health interventions. A mathematical model was developed together with an expression for the basic reproduction number (R0). The sensitivity of model predictions to unknown parameters determining the transmission of vCJD via infected blood was assessed under pessimistic modelling assumptions. We found that the size of the epidemic (up until 2080) was bounded above by 900 cases, with self-sustaining epidemics (R0>1) also possible; but the scenarios under which such epidemics could arise were found to be biologically implausible. Under optimistic assumptions, public health interventions reduced the upper bound to 250 and further still when only biologically plausible scenarios were considered. Our results support the belief that scenarios leading to large or self-sustaining epidemics are possible but unlikely, and that public health interventions were effective.

Entities:  

Mesh:

Year:  2007        PMID: 17287181      PMCID: PMC2373392          DOI: 10.1098/rsif.2007.0216

Source DB:  PubMed          Journal:  J R Soc Interface        ISSN: 1742-5662            Impact factor:   4.118


  25 in total

1.  Effectiveness of leucoreduction for removal of infectivity of transmissible spongiform encephalopathies from blood.

Authors:  Luisa Gregori; Nancy McCombie; Douglas Palmer; Paul Birch; Samuel O Sowemimo-Coker; Antonio Giulivi; Robert G Rohwer
Journal:  Lancet       Date:  2004 Aug 7-13       Impact factor: 79.321

2.  On the definition and the computation of the basic reproduction ratio R0 in models for infectious diseases in heterogeneous populations.

Authors:  O Diekmann; J A Heesterbeek; J A Metz
Journal:  J Math Biol       Date:  1990       Impact factor: 2.259

Review 3.  Pathogenesis and prevalence of variant Creutzfeldt-Jakob disease.

Authors:  David A Hilton
Journal:  J Pathol       Date:  2006-01       Impact factor: 7.996

4.  The same prion strain causes vCJD and BSE.

Authors:  A F Hill; M Desbruslais; S Joiner; K C Sidle; I Gowland; J Collinge; L J Doey; P Lantos
Journal:  Nature       Date:  1997-10-02       Impact factor: 49.962

5.  Pathogenesis of mouse scrapie: effect of route of inoculation on infectivity titres and dose-response curves.

Authors:  R H Kimberlin; C A Walker
Journal:  J Comp Pathol       Date:  1978-01       Impact factor: 1.311

Review 6.  Variant Creutzfeldt-Jakob disease transmission by plasma products: assessing and communicating risk in an era of scientific uncertainty.

Authors:  A Farrugia; J W Ironside; P Giangrande
Journal:  Vox Sang       Date:  2005-11       Impact factor: 2.144

7.  Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent.

Authors:  M E Bruce; R G Will; J W Ironside; I McConnell; D Drummond; A Suttie; L McCardle; A Chree; J Hope; C Birkett; S Cousens; H Fraser; C J Bostock
Journal:  Nature       Date:  1997-10-02       Impact factor: 49.962

Review 8.  Transmission of bovine spongiform encephalopathy and scrapie to mice: strain variation and the species barrier.

Authors:  M Bruce; A Chree; I McConnell; J Foster; G Pearson; H Fraser
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1994-03-29       Impact factor: 6.237

9.  Epidemiological determinants of the pattern and magnitude of the vCJD epidemic in Great Britain.

Authors:  A C Ghani; N M Ferguson; C A Donnelly; T J Hagenaars; R M Anderson
Journal:  Proc Biol Sci       Date:  1998-12-22       Impact factor: 5.349

10.  Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient.

Authors:  Alexander H Peden; Mark W Head; Diane L Ritchie; Jeanne E Bell; James W Ironside
Journal:  Lancet       Date:  2004 Aug 7-13       Impact factor: 79.321

View more
  10 in total

1.  Report of the Working Group 'Overall Blood Supply Strategy with Regard to Variant Creutzfeldt-Jakob Disease (vCJD)': Statement on the Development and Implementation of Test Systems Suitable for the Screening of Blood Donors for vCJD - Dated September 17, 2008.

Authors: 
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

2.  Factors determining the potential for onward transmission of variant Creutzfeldt-Jakob disease via surgical instruments.

Authors:  Tini Garske; Hester J T Ward; Paul Clarke; Robert G Will; Azra C Ghani
Journal:  J R Soc Interface       Date:  2006-12-22       Impact factor: 4.118

Review 3.  Health Technology Assessment of pathogen reduction technologies applied to plasma for clinical use.

Authors:  Americo Cicchetti; Alexandra Berrino; Marina Casini; Paola Codella; Giuseppina Facco; Alessandra Fiore; Giuseppe Marano; Marco Marchetti; Emanuela Midolo; Roberta Minacori; Pietro Refolo; Federica Romano; Matteo Ruggeri; Dario Sacchini; Antonio G Spagnolo; Irene Urbina; Stefania Vaglio; Giuliano Grazzini; Giancarlo M Liumbruno
Journal:  Blood Transfus       Date:  2016-07       Impact factor: 3.443

4.  Could immunomodulation be used to prevent prion diseases?

Authors:  Thomas Wisniewski; Fernando Goñi
Journal:  Expert Rev Anti Infect Ther       Date:  2012-03       Impact factor: 5.091

Review 5.  Immunomodulation for prion and prion-related diseases.

Authors:  Thomas Wisniewski; Fernando Goñi
Journal:  Expert Rev Vaccines       Date:  2010-12       Impact factor: 5.217

Review 6.  The importance of ongoing international surveillance for Creutzfeldt-Jakob disease.

Authors:  Neil Watson; Jean-Philippe Brandel; Alison Green; Peter Hermann; Anna Ladogana; Terri Lindsay; Janet Mackenzie; Maurizio Pocchiari; Colin Smith; Inga Zerr; Suvankar Pal
Journal:  Nat Rev Neurol       Date:  2021-05-10       Impact factor: 42.937

7.  Uncertainty in the tail of the variant Creutzfeldt-Jakob disease epidemic in the UK.

Authors:  Tini Garske; Azra C Ghani
Journal:  PLoS One       Date:  2010-12-23       Impact factor: 3.240

8.  Initial Results of a Prospective Study and Identification of New Strategies to Increase Traceability of Plasma-derived Medicines.

Authors:  Sheyda Najafi; Ali Vasheghani Farahani; Hedieh Keshavarz-Bahaghighat
Journal:  Iran J Pharm Res       Date:  2018       Impact factor: 1.696

9.  Prion infectivity in the spleen of a PRNP heterozygous individual with subclinical variant Creutzfeldt-Jakob disease.

Authors:  Matthew T Bishop; Abigail B Diack; Diane L Ritchie; James W Ironside; Robert G Will; Jean C Manson
Journal:  Brain       Date:  2013-02-28       Impact factor: 13.501

Review 10.  PMCA Applications for Prion Detection in Peripheral Tissues of Patients with Variant Creutzfeldt-Jakob Disease.

Authors:  Giorgio Giaccone; Fabio Moda
Journal:  Biomolecules       Date:  2020-03-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.